Project Grant R21DA063110
Award Date
4/15/25
Completion Date
3/31/27
Dollars Obligated
$234K
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Washington, DC, USA
Similar Awards
This $714,783 federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports a comprehensive research initiative to investigate the intersection of HIV infection and opioid use on inflammasome activation, neuroinflammation, and neurotoxicity. The project will employ neuropathology, ex vivo, and in vitro methodologies to analyze brain tissue samples from persons with and without HIV, and with varying...
This $3,472,327 federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to study the impact of poly-substance use on the crosstalk between microglia, astrocytes, and neurons that regulates HIV latency. Led by Case Western Reserve University, the project will utilize newly developed methods to derive authentic microglia, astrocytes, and neurons from induced pluripotent stem cells (iPSCs) to investigate...
This $2,426,074 federal Project Grant award from the National Institute on Drug Abuse (NIDA) under CFDA 93.279 - Drug Use and Addiction Research Programs will support research to compare the effects of different medications for opioid use disorder (MOUD) on inflammation and neurocognition in people living with HIV. The research, led by Yale University, aims to evaluate how opioid agonist versus antagonist MOUD treatments impact inflammation and epigenetic changes in the central nervous system of...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $777,398 to Trustees of Boston University's medical campus to investigate the molecular mechanisms linking HIV infection and opioid use disorder that drive neuroinflammation and HIV-associated neurocognitive disorders (HAND). The key focus of the research is to use primary human iPSC-derived microglia cultures to study how HIV infection and...
This Project Grant award from the National Institute on Drug Abuse (NIDA), part of the Drug Use and Addiction Research Programs (CFDA 93.279), provides $1,411,610 in funding over a 5-year period from July 1, 2024 to April 30, 2029. The grant supports research to investigate the combined effects of HIV transactivator of transcription (Tat) protein and opioids on aberrant glial-neuronal communication, with a focus on the role of extracellular microRNAs. The research team at the University of...
This $3,904,555 Project Grant was awarded on June 15, 2024 by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant supports research into the mechanisms by which the synthetic opioid fentanyl, alone and in combination with the drug xylazine ("tranq"), interacts with HIV to disrupt the structure and function of medium spiny neurons in the striatum. The research will systematically explore the roles of mu-opioid...
This $1,192,612 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to integrate HIV prevention services into clinical care settings for people with opioid use disorder (OUD). The key objectives are to: Conduct a systematic assessment of healthcare utilization, HIV prevention services, and medication for OUD using claims and emergency department data (Specific Aim 1). Use an evidence-based quality...
This $708,397 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research on the role of inflammasomes in opioid-induced pain in the context of HIV. The research aims to construct a cell atlas of opioid-targeted inflammasomes in the spinal cord of HIV pain models, elucidate the role of Wnt5a signaling in establishing inflammasome cell maps, and determine the contribution of glial-specific NLRP3 to...
This Project Grant award, totaling $1,381,500.00, was provided by the National Institute on Drug Abuse (part of the National Institutes of Health) under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant aims to explore the role of sex differences in establishing and maintaining HIV/SIV reservoirs in the context of opioid use. The key products and services to be delivered under this award include: Utilizing SIV-infected rhesus macaques as a model to comprehensively document...
This federal Project Grant award, valued at $5,849,631.00 and effective from May 1, 2024 to February 28, 2029, was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant supports research on developing long-acting injectable treatments for HIV among people who inject drugs (PWID), a population that lags behind others in viral suppression. The primary awardee is The Johns Hopkins University, which will collaborate with...